Futibatinib (TAS-120) is a highly selective, irreversible, and orally bioavailable inhibitor of FGFR1-4. It demonstrates potent activity in preclinical models of FGFR-dysregulated cancers, supporting its investigation in both in vitro and in vivo research for oncology and targeted therapy applications.